Fierce Pharma
SEPTEMBER 5, 2024
AstraZeneca has found its employees’ practices under the microscope of Chinese law enforcement years after an insurance fraud case. | AstraZeneca has found its employees’ practices under the microscope of Chinese law enforcement years after an insurance fraud case.
Pharma IQ
SEPTEMBER 5, 2024
Explore how digital transformation, particularly cloud technology and AI enhances efficiency and patient outcomes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
SEPTEMBER 5, 2024
Johnson & Johnson’s newly FDA-approved lung cancer combination of Rybrevant and Lazcluze is inching ever closer to a statistically significant survival showing, which could help it better chall | Johnson & Johnson’s newly FDA-approved lung cancer combination of Rybrevant and Lazcluze is inching ever closer to a statistically significant survival showing, which could help it better challenge AstraZeneca’s Tagrisso.
pharmaphorum
SEPTEMBER 5, 2024
Listen to the podcast interview with Manny Belabe from ArisGlobal as he discusses The Life Sciences Generative AI Council and its role in creating a sustainable technological future. Gain insights into the future of AI in life sciences.
Fierce Pharma
SEPTEMBER 5, 2024
With dwindling funds after a prior snub from the FDA, ImmunityBio’s journey to bag approval for its Merck-rivaling bladder cancer drug Anktiva wasn’t easy. | The drugmaker laid off 20 employees as it attempts to recoup from dwindling funds during its Anktiva launch in bladder cancer.
pharmaphorum
SEPTEMBER 5, 2024
A "small number" of AstraZeneca employees have been detained in China in an investigation into suspected data privacy and drug import breaches
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
SEPTEMBER 5, 2024
Samsung announced its plans to acquire French medtech startup Sonio. The startup’s AI platform, which was cleared by the FDA last year, automates ultrasound reporting so that healthcare providers can conduct these exams with greater accuracy and efficiency. The post Samsung Acquires AI-Powered Prenatal Ultrasound Startup appeared first on MedCity News.
Fierce Pharma
SEPTEMBER 5, 2024
After running up against a roadblock earlier this summer, the controversial BIOSECURE Act could gain new momentum next week. | Next week, the U.S. House of Representatives is slated to consider the BIOSECURE Act, which was introduced in January and seeks to halt federal contracts with certain Chinese biotech equipment and service providers over national security concerns.
MedCity News
SEPTEMBER 5, 2024
Cyril Philip, vice president of digital health ventures with Bon Secours Mercy Health and digital ventures lead for Accrete Health Partners, is taking part in a panel discussion at INVEST Digital Health in Dallas on September 18. In response to emailed questions, he addressed some of these challenges. The post What Challenges Do Implementing New Tech at a Hospital Pose?
Fierce Pharma
SEPTEMBER 5, 2024
Insights from Planning Committee Member Shirish Ingawale | Why is PDA’s Universe of Pre-Filled Syringes and Injection Devices Conference the must-attend event of the year? Get an exclusive preview from expert Shirish Ingawale!
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
SEPTEMBER 5, 2024
Omada Health is a respected health tech company but what do customers see it? A flesh and blood and an AI analysis follows. The post What Do Consumers and AI Think Of Omada Health? appeared first on MedCity News.
Fierce Pharma
SEPTEMBER 5, 2024
By adding $1.1 billion to its settlement proposal, Johnson & Johnson is inching closer to resolving approximately 62,000 personal injury lawsuits from those who claim their cancers were caused | By adding $1.1 billion to its settlement proposal, Johnson & Johnson is inching closer to resolving approximately 62,000 personal injury lawsuits from those who claim their cancers were caused by the company’s talcum powder products.
Pharmaceutical Commerce
SEPTEMBER 5, 2024
In the second part of her interview with Pharma Commerce Editor Nicholas Saraceno, Ilisa B.G. Bernstein, President of Bernstein Rx Solutions, LLC, discusses the best practices that compliance teams should consider as the end of the stabilization period approaches this November.
MedCity News
SEPTEMBER 5, 2024
Dr. Tina Saw is the founder and CEO of Oral Genome, a healthcare startup that’s developing saliva tests to detect and prevent oral diseases. In response to emailed questions, Saw talked about her company’s approach. The post This Diagnostic Startup Uses Saliva to Detect Oral Diseases Earlier appeared first on MedCity News.
pharmaphorum
SEPTEMBER 5, 2024
Click Therapeutics' digital therapeutic for migraine clears late-stage study using an endpoint used to test drugs, clearing the way for regulatory filing.
MedCity News
SEPTEMBER 5, 2024
Positive preliminary results for Eli Lilly’s efsitora alfa continue to build the case for this once-weekly insulin in type 2 diabetes patients. Lilly is trying to catch up to Novo Nordisk’s once weekly insulin icodec, which is commercially available in several markets around the world but is not yet approved by the FDA. The post Eli Lilly Moves Closer to Bringing Diabetes Patients a Once-Weekly Insulin Alternative appeared first on MedCity News.
pharmaphorum
SEPTEMBER 5, 2024
J&J is reported to have raised its offer to settle claims that its talc products caused cancer by $1.1bn, as it reaches agreement with a holdout law firm.
MedCity News
SEPTEMBER 5, 2024
Switching to a new transportation management vendor can bring much-needed relief to member populations and plan staff managing the programs. Here are few tips to help make the transition easier. The post Three Critical Steps to Ensure Health Plans’ Smooth Transition of Transportation Management Services appeared first on MedCity News.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
pharmaphorum
SEPTEMBER 5, 2024
EU General Court suspends decision to revoke the license for Advanz Pharma's primary biliary cholangitis drug Ocaliva.
MedCity News
SEPTEMBER 5, 2024
Let’s envision a healthcare system where caregiving is valued as the essential work it is. Where technology and policy work hand in hand and no one has to choose between caring for a loved one and pursuing their own health and career goals. The post While America Rested on Labor Day, The Invisible Healthcare Workforce Carried On appeared first on MedCity News.
Pharmaceutical Commerce
SEPTEMBER 5, 2024
Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.
MedCity News
SEPTEMBER 5, 2024
Through a new partnership announced Thursday, SEQSTER will be PatientsLikeMe’s electronic health record provider. The post SEQSTER, PatientsLikeMe Launch Patient Data Partnership appeared first on MedCity News.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
SEPTEMBER 5, 2024
Eli Lilly and EVA Pharma have formed a partnership to increase the availability of baricitinib in 49 African countries by 2030.
pharmaphorum
SEPTEMBER 5, 2024
ArsenalBio raises $325m for programmable CAR-T platform Phil.
Pharmaceutical Technology
SEPTEMBER 5, 2024
Haya could secure up to $1bn after hitting preclinical, clinical, and commercial milestones with drugs that emerge from this deal.
PharmaTimes
SEPTEMBER 5, 2024
Pre-clinical data of VTX-806 in demonstrated normalisation of metabolic parameters
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Pharmaceutical Technology
SEPTEMBER 5, 2024
Moderna is currently running a Phase I/II trial of the mRNA mpox vaccine mRNA-1769 in healthy participants.
PharmaTech
SEPTEMBER 5, 2024
Qualifying material suppliers is a crucial step in ensuring safe and effective drug products.
European Pharmaceutical Review
SEPTEMBER 5, 2024
Reactive oxygen species (ROS) are unstable molecules that react with other molecules in a cell and can damage DNA, RNA and proteins. NADPH oxidases (NOX) are a group of enzymes responsible for producing ROS, the production of which is linked with inflammation and fibrotic conditions. There is speculation that reducing levels of ROS could help find treatments for a range of diseases including cancer as well as inflammatory and fibrotic diseases.
PharmaTech
SEPTEMBER 5, 2024
This Behind the Headlines news roundup panel discussion covers news items such as the weight loss drugs battle between Novo Nordisk and Eli Lilly, entering new territory through Lilly’s partnership with HAYA Therapeutics and long non-coding sequence mining. There was much discussion on how the inflation reduction act and Medicare price controls may or may not pertain—given the uncertainty around the presidential election results, and subsequent policy directions.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Expert insights. Personalized for you.
363 
Let's personalize your content